Neos Therapeutics (NASDAQ:NEOS) Raised to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a sell rating to a hold rating in a research note published on Saturday morning, Zacks.com reports.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Shares of NASDAQ NEOS opened at $0.69 on Friday. The stock has a market cap of $34.82 million, a P/E ratio of -1.96 and a beta of 1.29. Neos Therapeutics has a 12-month low of $0.60 and a 12-month high of $2.15. The business’s fifty day simple moving average is $0.76 and its 200-day simple moving average is $1.13.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.06). The company had revenue of $14.49 million during the quarter. Neos Therapeutics had a negative net margin of 26.52% and a negative return on equity of 2,087.24%. As a group, sell-side analysts expect that Neos Therapeutics will post -0.23 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in shares of Neos Therapeutics by 23.0% in the first quarter. Wells Fargo & Company MN now owns 83,277 shares of the company’s stock valued at $63,000 after acquiring an additional 15,570 shares in the last quarter. Blair William & Co. IL acquired a new stake in Neos Therapeutics in the fourth quarter valued at $25,000. Jacobs Levy Equity Management Inc. acquired a new stake in Neos Therapeutics in the fourth quarter valued at $184,000. Goldman Sachs Group Inc. raised its stake in Neos Therapeutics by 5.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,559,374 shares of the company’s stock valued at $3,865,000 after buying an additional 135,859 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Neos Therapeutics by 63.4% in the fourth quarter. Renaissance Technologies LLC now owns 666,868 shares of the company’s stock valued at $1,007,000 after buying an additional 258,706 shares in the last quarter. Institutional investors and hedge funds own 39.19% of the company’s stock.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Recommended Story: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.